Bulletin
Investor Alert

Market Pulse Archives

Sept. 28, 2021, 6:41 a.m. EDT

Eli Lilly to reduce list price of Insulin Lispro injection by an additional 40% from Jan. 1, restoring it to 2008 levels

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eli Lilly & Co. (LLY)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

LLY

Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY +0.50% said Tuesday it is reducing the list price of Insulin Lispro Injection in the U.S. by another 40% effective Jan. 1, 2022, bringing the price down to 2008 levels. "Lilly's Insulin Lispro Injection, 100 units/mL -- first introduced at half the list price of branded Humalog(R) (insulin lispro injection, 100 units/mL) in 2019 -- will now have a 70% lower list price than Humalog U-100," the company said in a statement. People using any of Lilly's insulin products can fill their monthly prescription for $35 through the Lilly Insulin Value Program, for those with commercial insurance or who are uninsured, while seniors can use a program that is part of Medicare Part D plans. "We hope this additional 40 percent cut can expand affordable insulin to more people with diabetes," Lilly Chief Executive David Ricks said in a statement. Lilly shares were down 0.4% premarket.

/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 237.88
+1.19 +0.50%
Volume: 2.60M
Oct. 15, 2021 4:02p
P/E Ratio
35.73
Dividend Yield
1.43%
Market Cap
$227.55 billion
Rev. per Employee
$701,137
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.